{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:03:36Z","timestamp":1790456616376,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/coc.0b013e3181b9cd2f","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T05:24:09Z","timestamp":1269667449000},"page":"481-488","source":"Crossref","is-referenced-by-count":141,"title":["High-Dose-Rate Prostate Brachytherapy"],"prefix":"10.1097","volume":"33","author":[{"given":"Alvaro A.","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Demanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Schour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ghilezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1877::AID-CNCR32>3.0.CO;2-5","article-title":"The national Cancer Data Base Report on increase use of brachytherapy for the treatment of patients with prostate carcinoma in the USA.","volume":"86","author":"Mettlin","year":"1999","journal-title":"Cancer"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2004.10.062","article-title":"The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.","volume":"22","author":"Cooperberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"R3-11-20210128","first-page":"152","article-title":"Survival advantage for prostate cancer patients treated with high-dose 3-dimensional conformal radiotherapy.","volume":"5","author":"Hanks","year":"1999","journal-title":"Cancer J Sci Am"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/radiology.209.1.9769828","article-title":"Locally advanced prostate cancer: long term toxicity outcome after 3-dimensional conformal radiation therapy-a dose escalation study.","volume":"209","author":"Zelefsky","year":"1998","journal-title":"Radiology"},{"key":"R5-11-20210128","first-page":"113","article-title":"Transperineal ultrasound-guided implantation of the prostate: morbidity and complications.","volume":"137","author":"Blasko","year":"1991","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0360-3016(96)00609-8","article-title":"Biochemical disease-free survival following I-125 prostate implantation.","volume":"37","author":"Beyer","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0360-3016(00)01463-2","article-title":"Phase II prospective study of the use of conformal high-dose rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.","volume":"49","author":"Martinez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy treatment reduces toxicity compared to low dose rate palladium seeds.","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High dose rate intensity-modulated radiotherapy with external beam radiotherapy for prostate cancer: California endocurietherapy 10-year results.","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-11-20210128","first-page":"245","article-title":"Irradiation of localized prostatic carcinoma with a combination of high-dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland.","volume":"47","author":"Borghede","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2003.08.003","article-title":"Long-term outcome by risk factors using conformal High Dose Rate Brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.","volume":"58","author":"Galalae","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients.","volume":"53","author":"Zelefski","year":"2002","journal-title":"Int. J Radiat Oncol Biol Phys"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0360-3016(01)01552-8","article-title":"Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer.","volume":"50","author":"Martinez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0360-3016(93)90546-8","article-title":"Concurrent treatment planning for outpatient high dose rate prostate template implants.","volume":"27","author":"Edmundson","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0360-3016(95)00276-6","article-title":"Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy.","volume":"33","author":"Edmundson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial.","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/01.ju.0000052720.62999.a9","article-title":"Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.","volume":"169","author":"Martinez","year":"2003","journal-title":"J Urol"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0167-8140(00)00291-7","article-title":"High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method.","volume":"57","author":"Demanes","year":"2000","journal-title":"Radiother Oncol"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0360-3016(94)00599-G","article-title":"Dosimetry guidelines to minimized urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.","volume":"32","author":"Wallner","year":"1995","journal-title":"IntJ Radiat Oncol Biol Phys"},{"key":"R20-11-20210128","first-page":"517","article-title":"Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.","volume":"17","author":"Zelefsky","year":"1999","journal-title":"Oncology"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0360-3016(00)00632-5","article-title":"Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer.","volume":"48","author":"Gelbaum","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0360-3016(01)01651-0","article-title":"A simple analytic derivation suggests that prostate cancer \u03b1\/\u03b2 ratio is low.","volume":"51","author":"King","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(00)00687-8","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I\/II clinical trial.","volume":"48","author":"Yoshioka","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show a high sensitivity to fractionation (low \u03b1\/\u03b2 ratio), similar to late-responding normal tissue.","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0360-3016(02)03383-7","article-title":"Hypofractionated conformal radiotherapy of prostate cancer: 5-year outcome analysis.","volume":"54","author":"Logue","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0360-3016(02)04146-9","article-title":"Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase iii randomized trial.","volume":"55","author":"Yeoh","year":"2003","journal-title":"Int. J Radiat Oncol Biol Phys"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0360-3016(03)00132-9","article-title":"What hypofractionated protocols should be tested for prostate cancer?","volume":"56","author":"Fowler","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1148\/105.1.135","article-title":"The phenomenon of reoxygenation and its implications for fractionated radiotherapy.","author":"Kallman","year":"1972","journal-title":"Radiology"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0360-3016(00)00550-2","article-title":"Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.","volume":"47","author":"Zelefsky","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201010000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:31Z","timestamp":1786040071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201010000-00011"}},"subtitle":["An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer"],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181b9cd2f","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}